| 1 |
cytotoxic T-lymphocyte-associated protein 4
(1469 times)
|
Neoplasms
(367 times)
|
PD-1 (326 times)
PD-L1 (197 times)
ICIs (88 times)
|
1995 Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4). A disulfide-linked homodimer binds two CD86 molecules.
|
| 2 |
cytotoxic T-lymphocyte antigen-4
(1188 times)
|
Allergy and Immunology
(276 times)
|
PD-1 (215 times)
PD-L1 (104 times)
OR (61 times)
|
1995 Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts.
|
| 3 |
CTL-associated antigen 4
(27 times)
|
Neoplasms
(14 times)
|
CTLs (3 times)
TME (3 times)
DC (2 times)
|
2004 CTLA-4-dependent mechanisms prevent T cell induced-liver pathology during the erythrocyte stage of Plasmodium berghei malaria.
|
| 4 |
cytotoxic T cell antigen 4
(14 times)
|
Neoplasms
(3 times)
|
OR (3 times)
PD-1 (2 times)
SNPs (2 times)
|
2003 Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity.
|
| 5 |
CTL antigen 4
(13 times)
|
Neoplasms
(11 times)
|
PD-1 (3 times)
PD-L1 (2 times)
CR (1 time)
|
2003 Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist.
|
| 6 |
CTL-associated protein 4
(6 times)
|
Allergy and Immunology
(3 times)
|
Tim-3 (3 times)
BTLA (2 times)
IC (2 times)
|
2009 Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade.
|
| 7 |
anti-CTL antigen-4
(4 times)
|
Neoplasms
(4 times)
|
mAb (2 times)
PD-1 (2 times)
GITR (1 time)
|
2006 Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.
|
| 8 |
cytotoxic T lymphocyte Ag-4
(3 times)
|
Allergy and Immunology
(2 times)
|
ICI (1 time)
irAE (1 time)
SEB (1 time)
|
1997 Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death.
|
| 9 |
anti-cytotoxic T-lymphocyte 4
(2 times)
|
Allergy and Immunology
(1 time)
|
ICI (1 time)
IL (1 time)
IMDC (1 time)
|
2017 Immune correlates of clinical outcome in melanoma.
|
| 10 |
cell lymphocyte-associated molecule-4
(2 times)
|
Genetics
(1 time)
|
ATD (1 time)
HT (1 time)
TRAb (1 time)
|
2002 Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
|
| 11 |
cytotoxic T cell-associated protein 4
(2 times)
|
Hematology
(1 time)
|
PD-1 (2 times)
CRC (1 time)
dMMR (1 time)
|
2019 Modulation of immune checkpoint molecule expression in mantle cell lymphoma.
|
| 12 |
anti-cytotoxic T-lymphocyte antigen-4 monoclonal
(1 time)
|
Neoplasms
(1 time)
|
---
|
2014 An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.
|
| 13 |
case of autoimmune hypophysitis induced by the anticytotoxic T-lymphocyte antigen-4
(1 time)
|
Endocrinology
(1 time)
|
irAE (1 time)
|
2015 Anticytotoxic T-lymphocyte antigen-4 induced autoimmune hypophysitis: a case report and literature review.
|
| 14 |
CD28 lead to signaling activation, while T-lymphocyte antigen 4
(1 time)
|
Allergy and Immunology
(1 time)
|
PD-1 (1 time)
PI3K (1 time)
|
2021 Molecular interactions of the CTLA-4 cytoplasmic region with the phosphoinositide 3-kinase SH2 domains.
|
| 15 |
change in the levels of T-lymphocyte-associated antigen 4
(1 time)
|
Neurosurgery
(1 time)
|
ELISA (1 time)
GKR (1 time)
PD-L1 (1 time)
|
2019 Gamma knife radiosurgery compared to whole brain radiation therapy enhances immunity via immunoregulatory molecules in patients with metastatic brain tumours.
|
| 16 |
checkpoint inhibitors, namely anticytotoxic T-lymphocyte antigen-4
(1 time)
|
|
ACTH (1 time)
MRI (1 time)
NSCLC (1 time)
|
2018 Two Cases of Atezolizumab-Induced Hypophysitis.
|
| 17 |
clarify the role of the T-lymphocyte-associated-4
(1 time)
|
Endocrinology
(1 time)
|
Ab (1 time)
AITD (1 time)
RFLP (1 time)
|
2003 Association of the CTLA-4 gene 49 A/G polymorphism with type 1 diabetes and autoimmune thyroid disease in Japanese children.
|
| 18 |
combinations of the following monoclonal antibodies: CD3-PE/cy5, CD4-APC, CD8-APC, CD152-PE
(1 time)
|
Medicine
(1 time)
|
CHB (1 time)
PBMCs (1 time)
PD-L1 (1 time)
|
2013 CTLA-4 and its ligands on the surface of T- and B-lymphocyte subsets in chronic hepatitis B virus infection.
|
| 19 |
common T lymphocyte antigen 4
(1 time)
|
Drug Therapy
(1 time)
|
PD-1 (1 time)
|
2015 The genetic basis of new treatment modalities in melanoma.
|
| 20 |
CONTENT: T-lymphocyte-associated antigen 4
(1 time)
|
Communicable Diseases
(1 time)
|
ESCMID (1 time)
ESGICH (1 time)
mAb (1 time)
|
2018 ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
|
| 21 |
cytokine suppressors such as T lymphocyte-associated antigen-4
(1 time)
|
Complementary Therapies
(1 time)
|
ELISA (1 time)
ICOS (1 time)
IFN-gamma (1 time)
|
2012 Repressor of GATA-3 can negatively regulate the expression of T cell cytokines through modulation on inducible costimulator.
|
| 22 |
cytotoxic T cell associated antigen-4
(1 time)
|
Chemistry
(1 time)
|
MAPK (1 time)
MEK (1 time)
PD-L1 (1 time)
|
2020 Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade.
|
| 23 |
cytotoxic T-cell-associated Ag-4
(1 time)
|
Cells
(1 time)
|
BM-MSCs (1 time)
DT-MSCs (1 time)
GVHD (1 time)
|
2019 Mesenchymal Stem/Stromal Cells Derived from Dental Tissues: A Comparative In Vitro Evaluation of Their Immunoregulatory Properties Against T cells.
|
| 24 |
cytotoxic T-lymphocyte attenuator-4
(1 time)
|
Communicable Diseases
(1 time)
|
LAG-3 (1 time)
PD-1 (1 time)
|
2015 Induction of Inhibitory Receptors on T Cells During Plasmodium vivax Malaria Impairs Cytokine Production.
|
A Search Service for Abbreviation / Long Form